ZNTL ZENTALIS PHARMACEUTICALS
Price Chart
Executive Summary
Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The key catalyst is the selection of the 400mg QD 5:2 dose for azenosertib monotherapy in Cyclin E1-positive PROC, advancing the DENALI Phase 2 trial toward a topline readout by year-end 2026, which could support an accelerated approval pathway. Cash of $211.8M provides runway into late 2027, funding key milestones including the ASPENOVA Phase 3 trial initiation.
Actionable Insight
The dose selection and ASPENOVA initiation de-risk the regulatory pathway for azenosertib. The DENALI topline readout by year-end 2026 is the next major catalyst — positive data could drive significant upside given the 50% PROC patient population with no approved biomarker-specific therapy. Monitor for FDA feedback on accelerated approval and any partnership or financing announcements given the cash runway into late 2027.
Key Facts
- Q1 2026 EPS -$0.50 vs consensus -$0.52 (4.5% beat)
- Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC
- DENALI Part 2 topline readout expected by year-end 2026, potentially supporting accelerated approval
- ASPENOVA Phase 3 confirmatory trial initiated with first patient dosed
- Cash, cash equivalents and marketable securities of $211.8M as of March 31, 2026, providing runway into late 2027
- R&D expenses $28.7M in Q1 2026 vs $27.2M in Q1 2025; total operating expenses $37.9M vs $45.6M
- Net loss $35.4M in Q1 2026 vs $48.3M in Q1 2025
Financial Impact
EPS beat of $0.02 per share; cash burn of ~$34M in Q1 2026; no revenue reported
Risk Factors
- DENALI Part 2 topline data may not meet efficacy endpoints required for accelerated approval
- Competition from other WEE1 inhibitors and emerging therapies in PROC
- Cash runway only into late 2027; may require additional financing before reaching profitability
- Regulatory delays or changes in FDA accelerated approval requirements
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $3.51 awaiting T+1 | awaiting T+1 | — | $3.75 (+6.84%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $3.95 $3.72 | ▼ −5.82% | ▼ −5.10% | $3.75 (−5.06%) |
|
May 21, 2026
24d ago
|
Press Release
| $4.06 $3.96 | ▼ −2.46% | ▼ −3.05% | $3.75 (−7.64%) |
|
May 21, 2026
24d ago
|
8-K
| $4.06 $3.96 | ▼ −2.46% | ▼ −3.05% | $3.75 (−7.64%) |
|
May 12, 2026
4w ago
|
8-K
| $4.28 $4.28 | · 0.00% | ▲ +0.00% | $3.75 (−12.38%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.28 $4.28 | · 0.00% | ▲ +0.00% | $3.75 (−12.38%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $3.99 $3.84 | ▼ −3.76% | ▼ −4.78% | $3.75 (−6.02%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $4.64 $4.03 | ▼ −13.15% | ▼ −12.95% | $3.75 (−19.18%) |
|
Apr 17, 2026
8w ago
|
8-K
| $4.64 $4.03 | ▼ −13.15% | ▼ −12.95% | $3.75 (−19.18%) |
|
Apr 9, 2026
9w ago
|
8-K
| $4.42 $6.61 | ▲ +49.55% | ▲ +49.61% | $3.75 (−15.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access